HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...

-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Please provide your email address to receive an email when new articles are posted on . The European Commission has approved the subcutaneous formulation of Celltrion’s infliximab biosimilar for adult ...

Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Centocor have warned healthcare professionals via letter regarding risks of hepatotoxicity and pneumonia associated with the use of ...

Advantage plans do a better job than standalone Part D policies, albeit with important gap ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...

Results from the first study showed the overall efficacy at week 54 and the safety profile at week 6 of CT-P13 SC were comparable to CT-P13 IV. Celltrion Healthcare presented new findings at the ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...

Infliximab is used to treat a variety of inflammatory disorders; however, infusion reactions can occur that might necessitate discontinuation of treatment. A study in Sweden has evaluated the ...